ADHD Patch Opportunity Recent launch of XELSTRYM transdermal system (dextroamphetamine) positions the company in the U.S. stimulant therapy space for ADHD across adults and children, creating cross-sell and co-promotion opportunities for external analgesics and anti-inflammatory lines where pain management intersects with ADHD-related stress or sleep issues.

Pain Relief Portfolio Strong focus on external analgesic products such as medicated plaster, gel, and spray provides a ready market for partnerships with clinics, pharmacies, and DTC channels; explore contract manufacturing, private-label opportunities, or regional distribution deals to broaden geographic reach.

Global Expansion Fit With a history dating back to 1834 and a diversified product slate, there is potential to leverage international distribution networks for analgesic and anti-inflammatory products into newer markets, including spaces with rising demand for non-oral delivery formats.

R&D Collaboration Ongoing product development initiatives such as space-life and terrestrial living solutions suggest openness to collaboration on specialized delivery systems, medical devices, or companion products that meet niche healthcare needs and new regulatory pathways.

Clinical & Pain Intersection Past and ongoing clinical efforts around analgesia and cancer pain indicate opportunities to partner on strategic trials, investigator-sponsored studies, or hospital formularies for combination therapies or enhanced topical analgesic solutions.